The Babies Whose Deaths Were Blamed on Their Parents

Before newborn screening detected it, MCADD killed infants during ordinary illness. A stomach virus, a skipped feeding, a long night's sleep. The child appeared healthy. Then the child was dead. And in a significant number of documented cases, the parents were investigated for murder.

Medium-chain acyl-CoA dehydrogenase deficiency (MCADD) is a fatty acid oxidation disorder. The body cannot break down medium-chain fatty acids for energy. When a child with MCADD goes without food for more than a few hours, the body runs out of its primary fuel (glucose) and tries to switch to fat. It cannot complete the switch. Blood sugar crashes. Toxic intermediates accumulate. The brain shuts down. Without emergency glucose, the child dies.

MCADD was first described in 1982 by Kolvraa and colleagues. Before that, children with MCADD who died during a fasting crisis were given other explanations. Some were classified as Reye syndrome, a liver-brain condition that was itself poorly understood. Some were classified as sudden infant death syndrome (SIDS). And some were classified as homicide.

The Forensic Problem

A child with undiagnosed MCADD can die suddenly, at home, with no prior medical history to suggest anything wrong. The child was healthy yesterday. There are no visible injuries. The autopsy may show fatty infiltration of the liver, which a forensic pathologist unfamiliar with metabolic disease can interpret as evidence of poisoning or neglect.

MCADD accounts for roughly 1% of deaths previously attributed to SIDS. In families where more than one child died, the suspicion of foul play intensified. Roy Meadow, a British pediatrician, promoted a principle that became known as Meadow's Law: one sudden infant death is a tragedy, two is suspicious, three is murder until proved otherwise. Meadow's Law is now recognized as statistically illiterate. It ignored the basic genetics of autosomal recessive inheritance, in which two carrier parents have a 25% chance of passing the condition to each child. A family that loses two children to the same undiagnosed metabolic disorder is not a statistical improbability. It is exactly what Mendelian genetics predicts.

Sally Clark, a British solicitor, was convicted in 1999 of murdering her two infant sons. The prosecution relied on Meadow's testimony that the odds of two SIDS deaths in an affluent family were 1 in 73 million. That number was wrong. It treated each death as statistically independent, which is false when both children share the same parents and the same genetic risk. Clark spent more than three years in prison. Her conviction was overturned in 2003. She never recovered. She died in 2007 at age 42.

Kathleen Folbigg, in Australia, spent 20 years in prison after being convicted in 2003 of killing her four infant children. Her sons carried rare variants in the BSN gene associated with lethal cardiac arrhythmia. She was pardoned in 2023.

Patricia Stallings, in Missouri, was convicted in 1991 of murdering her infant son Ryan by antifreeze poisoning. While Stallings was in jail awaiting trial, she gave birth to a second child who was diagnosed with methylmalonic acidemia (MMA), a metabolic disorder whose byproducts can be confused with ethylene glycol on older toxicology tests. A biochemistry professor had Ryan's blood retested. The substance identified as antifreeze was a metabolic acid produced by MMA. Stallings was released. Prosecutors apologized. The case was dismissed.

These are the cases that made the news. They do not account for the families who were investigated, questioned, reported to child protective services, or separated from their surviving children on suspicion alone, without charges, without trial, and without a metabolic explanation ever being sought.

What Screening Changed

MCADD is one of the clearest success stories in newborn screening. The numbers are unambiguous.

Before screening, approximately 25% of children with undiagnosed MCADD died during their first metabolic crisis. An additional 16% survived with severe neurological damage. The first crisis typically occurred between 3 and 24 months of age, triggered by an ordinary childhood illness or a period of fasting.

After screening, the mortality rate dropped to under 2%. In well-managed populations, it approaches zero.

The screening test uses tandem mass spectrometry to measure medium-chain acylcarnitines, particularly octanoylcarnitine (C8), from a dried blood spot taken in the first days of life. The test is highly sensitive and specific. A single common mutation (c.985A>G) accounts for roughly 80% of MCADD cases in Northern European populations, where the condition affects approximately 1 in 10,000 to 25,000 births.

The treatment is straightforward. Children with MCADD must avoid prolonged fasting. During illness, they need supplemental glucose, either orally or intravenously. No special formula. No restricted diet. No daily medication. The intervention is knowledge: the family knows the child cannot safely go without food, and the emergency room knows to give glucose immediately if the child presents during illness.

The entire intervention is a $2 screening test at birth, a letter in the family's wallet explaining the condition, and a medical alert bracelet. The cost of missing the diagnosis is a dead child or a parent in prison for a death the parent did not cause.

The Conditions That Were Already There

MCADD was not new in 1982. It had been killing children for as long as humans have existed. What was new was the ability to see it. Before Kolvraa, Gregersen, and their colleagues identified the enzymatic defect, these deaths had no metabolic explanation. They were SIDS. They were Reye syndrome. They were suspected abuse. They were tragedies attributed to bad luck or bad parents.

The same pattern recurs across the newborn screening panel. The condition was always there. The deaths were always happening. The families were always being blamed, or left without answers, or both. What screening adds is visibility. The heel prick does not change the biology. It changes whether anyone knows to look.

Retrospective testing has confirmed MCADD in stored blood spots and tissue samples from children who died before screening was available. In some of those cases, siblings of the dead child were subsequently tested and found to carry the same mutations. In some of those cases, the siblings were alive and could be managed. In some, a second child had already died.

Every condition on the newborn screening panel has a version of this history: a period before detection, when the disease was invisible and the consequences were absorbed by families who had no name for what happened to them. MCADD is the condition where the consequences included a criminal investigation.

What Remains

MCADD screening is now nearly universal in developed nations. It was one of the first conditions added to expanded screening panels when tandem mass spectrometry entered newborn screening laboratories in the late 1990s and early 2000s. The United Kingdom, Australia, Germany, Canada, and most of the United States screen for MCADD. Large cohort outcome studies from these countries confirm that early detection and fasting avoidance prevent nearly all mortality and morbidity.

The condition is most prevalent in Northern European populations and much rarer in East Asian and African populations. In countries without expanded newborn screening, children with MCADD continue to die during their first fasting crisis. Their deaths continue to be classified as SIDS or unexplained. Their parents continue to be questioned.

The screening test exists. It costs less than a dollar per condition on a multiplexed panel. The treatment is education and vigilance. The alternative is a dead child and a grieving parent under suspicion. The arithmetic has been clear since the 1990s. The only variable is whether a country chooses to look.